# EDGAR Filing Document

**Accession Number:** 0001131399
**File Stem:** 0001654954-26-005250
**Filing Date:** 2026-5
**Character Count:** 3569
**Document Hash:** 936898d464f36f2360525c702c04f94d
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001654954-26-005250.hdr.sgml**: 20260522

**ACCESSION NUMBER**: 0001654954-26-005250

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20260522

**FILED AS OF DATE**: 20260522

**DATE AS OF CHANGE**: 20260522

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** GSK plc
- **CENTRAL INDEX KEY:** 0001131399
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** X0

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-15170
- **FILM NUMBER:** 261010726

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 79 NEW OXFORD STREET
- **CITY:** LONDON
- **PROVINCE COUNTRY:** X0
- **ZIP:** WC1A 1DG
- **BUSINESS PHONE:** 44 20 8047 5000

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 79 NEW OXFORD STREET
- **CITY:** LONDON
- **PROVINCE COUNTRY:** X0
- **ZIP:** WC1A 1DG

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** GSK PLC
- **DATE OF NAME CHANGE:** 20220516

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** GLAXOSMITHKLINE PLC
- **DATE OF NAME CHANGE:** 20010105

**UNITED STATES**

 **SECURITIES AND EXCHANGE COMMISSION**

 **Washington, D.C. 20549**

 **Form 6-K**

 **REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16**

 **UNDER THE SECURITIES EXCHANGE ACT OF 1934**

For the month of May 2026

Commission File Number 001-15170

 **GSK plc**

(Translation of registrant's name into English)

 **79 New Oxford Street, London, WC1A 1DG**

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F . . . .X. . . . Form 40-F . . . . . . . .

 **GSK plc**

GSK confirms that the Company's Q2 2026 results are due to be published via the London Stock Exchange on Tuesday 28 July 2026. GSK will also provide an update on portfolio growth opportunities.

The results announcement dates and respective record and dividend dates for the remainder of the financial year are set out below:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| <br>**Results**<br>| **Announcement date** | **Ordinary Shares Ex-dividend date** | **American Depositary Shares Ex-dividend date** | **Record date** | **Last date for DRIP elections** | **Payable** |
| **Q2 2026** | Tuesday 28 July 2026 | Thursday 13 August 2026 | <br> Friday 14 August 2026<br>| Friday 14 August 2026 | Thursday 17 September 2026 | Thursday 8 October 2026 |
| **Q3 2026** | <br> Wednesday 28 October 2026<br>| Thursday 12 November 2026 | Friday 13 November 2026 | Friday 13 November 2026 | Monday 14 December 2026 | Thursday 7 January 2027 |
| **Q4 2026** | <br> Wednesday 3 February 2027<br>| Thursday 18 February 2027 | Friday 19 February 2027 | Friday 19 February 2027 | Tuesday 16 March 2027 | Thursday 8 April 2027 |

---

These dates are indicative and may be subject to change.

 **V A Whyte**

 **Company Secretary**

22 May 2026

 **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

---

| | |
|:---|:---|
|  | **GSK plc** |
|  | (Registrant) |
| Date: May 22, 2026 |  |
|  | By:/s/ VICTORIA WHYTE<br> -------------------------- |
|  | Victoria Whyte |
|  | Authorised Signatory for and on |
|  | behalf of GSK plc |

---